LOGO
pl en

Impact of time-interval between surgery and institution of chemotherapy on prognosis in FIGO stage III ovarian cancer patients

Michał Starnawski1, Mariusz Bidziński2

Affiliacja i adres do korespondencji
GIN ONKOL 2006, 4 (3), p. 177-185
Streszczenie

Ovarian cancer is the 5th most common malignancy in Polish women and is the 4th most common cause of death. Surgical treatment with subsequent platinum derivates-based chemotherapy combined with paclitaxel is the cornerstone of treatment of far advanced cases. The aim of this paper was to analyze patients treated since 1995 thru 1999 for FIGO stage III ovarian cancer. The primary end-point was progression-free survival (PFS). Based on our results, time interval between surgery and institution of chemotherapy had no influence on PFS in the study population. Median PFSs for particular quartiles were 8.4 months, 4.9 months, 7.8 months and 7.2 months respectively. Survival curves for these subgroups did not differ significantly (log rank test, p=0.74). Similar results were obtained when analyzing two groups of patients: those undergoing optimal surgical resection and those, in whom optimal procedure was impossible. In conclusion, time interval between surgery and adjuvant chemotherapy does not influence prognosis measured as progression-free survival in FIGO stage III ovarian cancer patients.

Słowa kluczowe
ovarian cancer, surgery, time interval, chemotherapy